ABAM Transitional Maintenance of Certification

Transitional Maintenance of Certification (tMOC) is a fundamental part of addiction medicine certification for current ABAM Diplomates. For more information or questions about the ABAM tMOC program, visit ABAM's website.

All of the courses below have been approved by the American Board of Addiction Medicine for tMOC.

ABAM tMOC Approved Courses

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Staten Island, NY - Thursday, September 19, 2019

    Contains 8 Component(s), Includes Credits

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.

    image

        

    image


    Thursday, September 19, 2019 | 9:00 am - 1:30 pm

    South Beach Psychiatric Center
    777 Seaview Avenue
    Administrative Building, 2nd Floor, TV Studio
    Staten Island, NY 10305

    Hosted by NYDOH

    Online Portion Due: Wednesday, September 18, 2019

    Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

    This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

    Getting started: To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."

     If you have any questions, please contact education@ASAM.org.

    1. Locate the box on the right that says “View Course" and click “View Course"
      1. A new window will open with the course. Be sure your pop-up blocker is turned off.
    2. Complete Module 1 and Module 2 (equivalent to four hours of instruction)
    3. You will be required to pass all CME Quizzes with a grade of 70% or higher
    4. Upon completion of both the two online modules and four hours of live, in-person instruction, you will be able to claim CME credit through the ASAM e-Learning Center




    Learning Objectives

    Module 1

    1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
    2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
    3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
    4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
    5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

    Module 2

    1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
    2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
    3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

    Module 3

    1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
    2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
    3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

    Overall

    Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

    CME Information and Disclosure Listing

    Date of Release: July 2015 

    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this enduring material for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    The American Society of Addiction Medicine designates this live activity for a maximum of AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of AMA PRA Category 1 Credit(s) to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone


    1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
    2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

      HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

      NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:




      If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.


    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

    Qualify 

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Apply

    SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

    Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

    If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

  • Pain Management & Opioids: Balancing Risks & Benefits - Updated (2.5 CME)

    Contains 11 Component(s), Includes Credits

    Earn a maximum of 2.5 AMA PRA Category 1™ Credit(s) while learning about the latest science, clinical guidelines, and policies around pain and opioids and getting the tools you need to provide evidence-based pain treatment.

    image

    The misuse of opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

    • From 1999 to 2016 more than 630,000 people died from drug overdoses.
    • 115 Americans die every day from an opioid overdose.

    The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits curriculum is newly updated to reflect the latest information in this vital area of healthcare. The thoroughly revised curriculum addresses: the nature and pathophysiology of pain; assessing patients in pain; creating a pain treatment plan; initiating opioid therapy; managing patients on opioid analgesics; educating patients and caregivers; and understanding opioid use disorder. This program meets many states requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blue Print”), issued by the U.S. Food & Drug Administration in September 2018. 

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

    Adam Gordon

    MD, MPH, FACP, CMRO, DFASAM

    Adam Gordon, MD MPH FACP DFASAM CMRO is the Elbert F. and Marie Christensen Endowed Research Professor of Medicine and Psychiatry at the University of Utah School of Medicine and Chief of Addiction Medicine at the Salt Lake City VA Healthcare System. He is a board certified internal medicine (American Board of Internal Medicine) and addiction medicine physician (American Board of Addiction Medicine) and has received distinction in both fields as a Fellow in the American College of Physicians (FACP) and a Distinguished Fellow in the American Society of Addiction Medicine (DFASAM). Prior to moving to Salt Lake City in the Winter of 2017, he was a Professor of Medicine and Clinical and Translational Sciences and an Advisory Dean in Student Affairs at the University of Pittsburgh School of Medicine. He maintains an active internal medicine – addiction medicine practice and has been honored nationally for his community service and clinical activities.

    He has a 17-year track record of conducting clinical, health services, and implementation scienceresearch on the quality, equity, and efficiency of health care for vulnerable populations, including patients with opioid use and other substance disorders and/or who are homeless. Major themes of his current research include the identification and implementation of evidence-based care for patients with addiction disorders and understanding the intersection of pain syndromes, opioid misuse, and engagement into opioid use disorder treatment. He is a prior VA Health Services Research and Development Service Career Development Awardee. His research has been funded by the NIH, VA, AHRQ, PCORI, SAMHSA, among others. He has authored over 150 peer reviewed scientific papers, several books and book chapters, and hundreds of peer reviewed scholarly abstracts, presentations, and other work. He has been recognized with several national research awards for his research, including the Young Investigator of the Year from the Association for Medical Education and Research on Substance Abuse (AMERSA).

    His professional career has been noted for service to federal government, community initiatives, and mentoring. For example, he directs the Buprenorphine Initiative in the VA where he leads a national consult service to increase the implementation of medication treatment for opioid use disorder. He is the Director of the National Coordinating Center for the VA Office of Academic Affiliations Advanced Interdisciplinary Fellowship in Addiction Research and Treatment, where he coordinates educational activities for fellowship sites across the country. He serves as the Editor-in-Chief of Substance Abuse, the Board of Directors of the International Society of Addiction Journal Editors, and the Board of Directors of AMERSA. He has had leading positions with several organizations including American Society of Addiction Medicine (ASAM. Chair of Continuing Medical Education), Allegheny County Medical Society (President, Board of Directors), and Pennsylvania Medical Society (Board of Trustees).

    As a senior, tenured, faculty member, he is passionate about training the next generation of clinicians and clinical researchers. Apart from this advising of hundreds of medical students in his prior capacity as an Advisory Dean at the University of Pittsburgh, he has educated, trained, or mentored over 50 post-graduate scholars to be leaders in scholarly activities involving addiction treatment. His mentees have received research career development awards, large VA/NIH research grants, and local and national young investigator of the year awards. As a testament to his teaching and mentoring expertise, he was named as one of the inaugural VA Health Services Research and Development (HSR&D) National Mentor Network (MNet) mentors. In addition, he has received of research mentoring awards including from the University of Pittsburgh, the AMA, and AMERSA (2013 W. Anderson Spickard, Jr. Excellence in Mentorship Award).

    Adam lives with his wife, Margaret Conroy, MD MPH and children Lillian, Neil, and Martha in Salt Lake City, Utah. He enjoys gardening and tennis.

    CME Information and Disclosure Listing

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.  

    The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.  

    ASAM CME Committee

    Name

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FAPA, DFASAM, Chair

    None

     

     

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

     

    Zwaantje Hamming, FNP-C, CARN-AP

    None

     

     

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Sandy Metcalfe

    None

     

     

    Program Planning Committee

    Name

    Commercial Interest

    What was received?

    For what role?

    Herbert Malinoff, MD, FACP, DFASAM

    None

     

     

    Yngvild Olsen, MD, MPH

    None

     

     

    Theodore Parran, MD, FACP

    None

     

     

    Edwin Salsitz, MD, DFASAM

    None

     

     

    R. Corey Waller, MD, MS, FACEP

    None

     

     

    Faculty

    Name

    Commercial Interest

    What was received?

    For what role?

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

     

    ASAM CME Committee Reviewers

    Name

    Commercial Interest

    What was received?

    For what role?

    Jacob Bobrowski, MD, FAAFP

    None

     

     

    Anthony H. Dekker, DO, DFASAM

    None

     

     

    ASAM Medical Education Council

    Name

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair

    Pfizer

    Johnson & Johnson

    Pfizer Canada

    Grant funding

    Consulting Fees

    Consulting Fees

     Principal Investigator

    Consulting

    Consulting

    Daniel Alford, MD, MPH

    None

     

     

    Michael Fingerhood, MD, FACP, FASAM

    None

     

     

    Catherine R. Friedman, MD, FAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

      

    Miriam S. Komaromy, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Mark P. Schwartz, MD, DFASAM

    None

     

     

    Mark A. Weiner, MD, FASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Jennifer L. Butchart

    None

     

     

    Penny S. Mills, MBA

    None

     

     

     

  • Board Exam Study Tool (BEST) - 2019 (17 CME)

    Contains 5 Component(s), Includes Credits

    Earn a maximum of 17 CME while learning from the BEST. This study tool helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format.

    image


    The ASAM Board Examination Study Tool (BEST) helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format.*


    *Note: Live attendees of the 2019 ASAM Review Course in Addiction Medicine in Dallas, TX can opt to receive the 2019 BEST at a reduced price of $100 if they sign up for the BEST on-site. Register for the Review Course Now!


    The NEW 2019 BEST Includes:


    700 Board-Style Self-Assessment Questions
    • Developed, reviewed and mapped to the ABPM exam blueprint content areas by national experts
    • Flexible learning modes allow users to design their study sessions and focus on specific topics
    • Personalized Reporting 
    • Access personal performance analysis reports and create a personalized study guide based on responses to the question bank
    Excerpts and Highlights 
    • High-level summaries from select chapters from the newly released Principles of Addiction Medicine, Sixth Edition
    Glossary
    • Explore a list of important terms and definitions in the addiction medicine field
    Additional Resources
    • Review the presentations slides from the 2019 ASAM Review Course in Addiction Medicine
    • View a list of additional resources recommended by Review Course faculty by topic


    Registrants will have access to content and be able to claim CME for one year from the date they start the tool. 

    Please Note: Due to technical issues, the explanations/references will not appear for all questions. ASAM is working to resolve the issue. 


    Additional Board Exam Preparation resources and tools are also available.

    Goals and Objectives

    Upon completion of this education activity, participant should be able to:

    • Differentiate between important terms and definitions in the field of Addiction Medicine.
    • Distill knowledge on key points from the text, the Principles of Addiction Medicine, 6th edition and course slides
    • Appraise addiction patient cases and respond accurately to questions about next steps and treatment options.
    • Employ knowledge gained in the educational sections of the BEST to respond accurately to self-assessment questions.

    Participants of the 2019 ASAM Review Course in Addiction Medicine and other physicians who are preparing for the ABPM Certification Exam in Addiction Medicine.

    NameCommercial InterestsCompensation ReceivedRole
    Timothy Brennan MD, MPH, FASAMNoneNANA
    Jeffrey DeVido MDAltria/Philip MorrisStockInheritance
    Paul Earley MD, DFASAMAlkermes, Inc; DynamiCare Health, IncHonoraria; SalarySpeaker; VP of Medical Affairs
    James Finch MD, DFASAMNoneNANA
    Marc Fishman MD, DFASAMUS World Meds; AlkermesConsulting fee, Travel; HonorariaConsultant; Advisory Board
    David Galbis-Reig MD, DFASAMAscension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer BondStock & Bond in Retirement IRA; Stock Options; Ownership InterestsOwner; Advisory Board; PI; Consultant
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNoneNANA
    Adam Gordon, MD, MPHNoneNANA
    Leslie Hayes, MDNoneNANA
    Abigail Herron DO, DFASAMNoneNANA
    Petros Levounis MD, MA, FASAMNoneNANA
    Carla Marienfeld MDNoneNANA
    Ricardo Restrepo MD, MPH, FASAMNoneNANA
    Richard Ries MD, DFASAMNoneNANA
    Edwin Salsitz MD, DFASAMNoneNANA
    Sharon Stancliff MD, FASAMNoneNANA
    Timothy Wiegand MD, FACMT, FAACTNoneNANA
    Erin Zerbo, MDNoneNANA
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 17 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 17 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 17 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Impact of Nicotine and Other Stimulants on Sleep in Young Adults (1 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the impact of stimulants on sleep in young adults from The Journal of Addiction Medicine 2019.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the impact of stimulants on sleep in young adults in this journal article from The Journal of Addiction Medicine 2019. Michael D. Stein, MD, Celeste M. Caviness, PhD and Bradley J. Anderson, PhD


    Learning objectives: 

    1.) Explore the relationship of commonly used stimulant substances to poor sleep in quality in young adults

    2.) Assess the varying impact of different stimulants on sleep 

  • Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use (1 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about recovery and treatment with nonmedical opioid use from The Journal of Addiction Medicine 2019.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the recovery and treatment with nonmedical opioid use in this journal article from The Journal of Addiction Medicine 2019. Andrew S. Huhn, PhD, MBA, Kaitlyn R. Hay, MS, David Andrew Tompkins, MD, MHS, Kelley E. Dunn, PhD


    Learning objectives: 

    1.)  Identify recovery goals and treatment preferences to maximize treatment initiation and retention 

    2.)  Explain the proportion of out of treatment individuals with non-medical opioid use that have abstinent and non-abstinent recovery goals

    3.) Understand how patients can be matched to treatments, which can help promote early treatment satisfaction and retention


  • Opioid and Cannabis Co-Use among Adults with Chronic Pain: Relations to Substance Misuse, Mental Health, and Pain Experience(1 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about opioid and cannabis co-use among adults with chronic pain The Journal of Addiction Medicine 2019.

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about learning about opioid and cannabis co-use among adults with chronic pain in this journal article from The Journal of Addiction Medicine 2019. Andrew S. Huhn, PhD, MBA, Kaitlyn R. Hay, MS, David Andrew Tompkins, MD, MHS, Kelley E. Dunn, PhD


    Learning objectives: 

    1.)  Identify how the co-use of substances is generally associated with poorer outcomes than single substance use

    2.)  Understand how opioid and cannabis co-use is associated with higher anxiety and depression symptoms 



  • The ASAM Fundamentals of Addiction Medicine 40-Hour CME Program (Online)

    Contains 65 Product(s)

    ​The ASAM Fundamentals of Addiction Medicine 40-Hour Program is an innovative educational program empowering primary care and other providers to identify, treat, and/or refer patients at risk for or with addiction. The curriculum is designed for healthcare professionals who received little addiction education during their medical training.​


    image


    The ASAM Fundamentals of Addiction Medicine 40-Hour Program is an innovative educational program empowering primary care and other providers to identify, treat, and/or refer patients at risk for or with addiction. Participants will learn how to recognize, screen, treat and refer patients with substance use disorders through 40 CME hours of interactive, case-based learning. This program is designed for healthcare professionals who received little addiction education during their medical training including physicians, clinicians, and other healthcare providers in primary care, emergency/urgent care, treatment centers and general psychiatry settings.

    Why Participate

    • Help patients that are already in your practice and be a part of the solution to the one of the nation’s deadliest epidemics
    • Increase knowledge, skills and confidence for providers who may have received little or no addiction education during their medical training
    • Learn how to integrate addiction medicine and payment models into your existing practice
    • Connect with a community of colleagues and mentors for additional support with complex patients
    • Experience content created specifically for primary care and other providers based on extensive needs-assessment
    • Learn core competencies and knowledge needed to identify, treat, and refer patients with addiction to specialists when needed
    • Earn a certificate of completion from ASAM upon completion of the 40-Hour CME Program

    Curriculum Topics

    • Attitudes towards addiction and treating patients with addiction
    • Substance use disorders medications
    • Neurobiology of addiction
    • Screening, brief intervention, and referral to treatment (SBIRT)
    • Motivational interviewing
    • Medical and Psychiatric Co-morbidities
    • Diagnosing substance use disorders
    • Developing a treatment plan (including ASAM Criteria)
    • Special populations (such as adolescents, pregnant women, etc)
    • Referral to specialists

    Program Activities

    The ASAM Fundamentals of Addiction Medicine 40-Hour CME Program is comprised of five activities. All activities align with the nine identified addiction medicine competencies for primary care providers. ASAM has also gathered a collection of resources and tools reviewed by experts related to various topics of addiction medicine and working with patients at risk for or with substance use disorders (SUD) to supplement participant’s learning.   

    Registration to the program includes the online version of all activities. Participants may elect to complete activities in a live, in-person format when available to fulfill program requirements.  Additional fees may apply for live-in-person events. 

    Participants will have the opportunity to submit CME certificates for any of the required activities they have previously completed and will NOT need to re-take the activity. 

    ActivityDescriptionCME Hours
    The ASAM Fundamentals of Addiction Medicine WorkshopParticipants are recommended to take this activity first in order to get the most out of the 40-Hour Program. 

    An 8-hour online self-paced, case-based workshop in which participants will learn more about recognizing, screening, diagnosing and treating patients with addiction with an emphasis on alcohol, opioids, and tobacco. (Participants may elect to take the 8-hour live workshop to fulfill this requirement. Participants of the live 8-hour workshop who have not yet enrolled in the program will receive a discount towards the overall price of the ASAM Fundamentals of Addiction Medicine 40-Hour Program. See website for upcoming workshop dates).
    8
    The ASAM Treatment of Opioid Use Disorder Course Includes Waiver Qualifying RequirementsAn 8-hour online self-paced course that covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine under the Drug Abuse Treatment Act of 2000 (DATA 2000) and Comprehensive Addiction and Recovery Act (CARA). This course fulfills 8 of the 24 hours required for NPs and PAs under CARA. 8
    The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits CourseProvides necessary context for opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids. The course will also include information from the CDC guidelines and includes information provided by the FDA blueprint for Risk Evaluation and Mitigation Strategy (REMS) education.2.5
    Fundamentals of Addiction Medicine ECHO (FAME) Video Conferencing Series  
    (in collaboration with Project ECHO – University of New Mexico) 
    Participants use video conferencing to connect with a panel of addiction and multidisciplinary experts. Sessions are two hours, and include a 20 - 30 minute addiction didactic presentation and lively discussions on case presentations submitted by participants.  Participants must attend at least 4 (four) teleECHO sessions and present one case to fulfill this activity requirement.8
    Elective Topics Participants select from over 80 hours of CME on a broad range of topics, especially created to meet the needs of primary care physicians and clinicians. Participants may choose from the approved modules and topics based on their needs and the needs of their patients. Completion of additional FAME TeleECHO sessions beyond the required four are also eligible to fulfill this component. 

    Only activities approved for the "Elective Topics" activity will be accepted to fulfill this requirement.
    13.5
    TOTAL40


    If you experience any difficulties, please feel free to call the ASAM office at 301-656-3920 or email education@asam.org.


    Note:  This program is for providers who are seeking additional knowledge about addiction medicine. This is not a certification or designed to prepare providers for certification exams. Providers interested in becoming an ABMS certified Addiction Specialist should go to www.abpm.org and/or learn about Addiction Fellowship programs at https://www.addictionmedicinefoundation.org/.

    image


    Program Competencies

    The ASAM Fundamentals of Addiction Medicine 40-Hour Program seeks to help learners achieve nine identified competencies in the addiction medicine field. 

    1. Interact with patients and professional colleagues so as to display professionalism in all activities, by demonstrating commitment to the health and well-being of individuals and society through ethical practice, profession-led regulation, and high personal standards of behavior.
    2. Identify their feelings and attitudes that promote or prevent therapeutic responses to their patients with substance use disorders.
    3. Understand the addictive disorders as developmental biopsychosocial disorders.
    4. Take an evidence-based approach to detecting substance use disorders. 
    5. Respond to positive substance use screening results with brief counseling strategies, appropriate to the patient’s readiness to change.
    6. Use motivational interviewing with patients ambivalent about changing their substance use behavior.
    7. Conduct a biopsychosocial and developmental ambulatory assessment of an adult with a suspected SUD to match the patient to an appropriate level of care.
    8. List the indications, contraindications and duration of treatment of evidence based pharmacotherapy for alcohol, tobacco, and opioid use disorders and refer patient to specialty care where appropriate. 
    9. Reflect on the role of behavioral interventions for patients and families including formal intensive ambulatory and inpatient treatment and informal programs such as mutual aid groups in the recovery process for patients in their practice/ communities.

    View the full ASAM Fundamentals of Addiction Medicine 40-Hour CME Program Blueprint: Competencies and Curriculum Learning Objectives.

    The 40 hour CME curriculum is structured around these nine competencies, of which each competency has several learning objectives. Activities in the curriculum will align with at least one of the learning objectives.

    image


    Why Participate?


    Participants are saying....

    • “This is probably the best post-graduate training I've ever done…The webinar format was engaging and educational. I greatly appreciate the opportunity to have involved at that level.” – MD, Massachusetts
    • “Appreciate your effort to organize the training. It was a great experience. I'd definitely recommend this to my primary care colleagues.” – MD, Maryland
    • “…living in the Northeast, I’m afraid I get very provincial so it’s been really interesting to hear everybody…but it’s the across the country responses that have been so helpful.” – MD, Massachusetts
    • “Living in Alaska, the resources for substance abuse treatment is probably not as diversified as in other areas…so this clinic has been valuable to me… providing the information and talking, collaborating with other professions in the field to help provide the best care of the patients.” – NP, Alaska


    Extensive Development from Experts.... 

     

    The ASAM Fundamentals 40-Hour Program was developed over multiple years, beginning in 2013. ASAM’s committee of experts created, evaluated, and revised the Fundamentals program continuously to ensure providers received the highest quality, most up-to-date  education.


    Competency-Based Program Activities...


    The ASAM Fundamentals of Addiction Medicine 40-Hour Program is comprised of five components. All components and activities align with the nine identified addiction medicine competencies for primary care providers. ASAM has also gathered a collection of resources and tools reviewed by experts related to various topics of addiction medicine and working with patients at risk for or with substance use disorders (SUD) to supplement participant’s learning.   


    Positive Outcomes for Participants' Practice...

    Some of the most commonly reported changes as a result of the ASAM Fundamentals 40-Hour Program were:

    • Change in patient treatment plans
    • Change in approach to patients with SUDs
    • More frequent screening, e.g. screening all patients at least annually.
    • More use of screening tools or use of different screening tools.
    • More or better use of SBIRT
    • More or better use of MI techniques
    • Increased confidence in treating patients with addiction

    image


    ASAM Fundamentals of Addiction Medicine Workshop Planning Committee

    NameDisclosure
    Miriam S. Komaromy, MD, FACP, FASAM (Chair)No Financial Relationships or Conflicts of Interest
    Peter L. Selby MBBS, CCFP, FCFP, MHSc, DFASAM, (Immediate Past Chair)Johnson and Johnson: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment or other in-kind support;Pfizer: Consultant/Advisory Board, Other Research Support includes receipt of drugs, supplies, equipment
    Zwaantje H. Hamming, FNP-C, CARN-APNo Financial Relationships or Conflicts of Interest
    Marcia Jackson, PhDNo Financial Relationships or Conflicts of Interest
    Jill Mattingly, DHSc, MMSc, PA-CNo Financial Relationships or Conflicts of Interest
    Lipi Roy, MD, MPHNo Financial Relationships or Conflicts of Interest
    Kenneth A. Saffier, MD, FASAMNo Financial Relationships or Conflicts of Interest
    Mario F. San Bartolomé, MD, MBA, MRO, QME, FASAMNo Financial Relationships or Conflicts of Interest
    J. Paul Seale, MD, FASAMNo Financial Relationships or Conflicts of Interest
    Alexander Walley, MD, MSc, FASAM  No Financial Relationships or Conflicts of Interest


    ASAM CME Committee

    NameDisclosure
    Catherine Friedman, MD (Chair)No Financial Relationships or Conflicts of Interest
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNo Financial Relationships or Conflicts of Interest
    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRONo Financial Relationships or Conflicts of Interest
    Zwaantje H. Hamming, FNP-C, CARN-APNo Financial Relationships or Conflicts of Interest
    Noel Ilogu, MD, MRCP, DFASAMNo Financial Relationships or Conflicts of Interest
    Herbert L. Malinoff, MD, FACP, DFASAMNo Financial Relationships or Conflicts of Interest
    Edwin A. Salsitz, MD, DFASAMNo Financial Relationships or Conflicts of Interest

     

    Commercial Interest Definition

    A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

    image



    Disclosure of Commercial Support

    The American Society of Addiction gratefully acknowledges the support of the following companies in the development of The ASAM Fundamentals of Addiction Medicine Program.


    Indivior provided an unrestricted educational grant to assist with the development, implementation and evaluation of this Fundamentals Program. 

    image

    image

    Accreditation Council for Continuing Medical Education (ACCME)


    The American Society of Addiction Medicine has been awarded the highest level of Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) as a provider of continuing medical education (CME) for physicians. Accreditation in the ACCME System seeks to assure the medical community and the public that ASAM delivers education that is relevant to clinicians’ needs, evidence-based, evaluated for its effectiveness, and independent of commercial influence.

    The ACCME System employs a rigorous process for evaluating institutions' CME programs according to standards that reflect the values of the educator community and aim to accelerate learning, inspire change, and champion improvement in healthcare. Through participation in accredited CME, clinicians and teams drive improvement in their practice and optimize the care, health, and wellness of their patients.

    Please see individual sessions for accreditation information for specific offerings. 

  • ASAM 50th Annual Conference - Innovations in Addiction Medicine and Science - 2019 (85 CME)

    Contains 63 Product(s)

    Earn a maximum of 85 AMA PRA Category 1™ credits while learning about the latest innovations in Addiction Medicine and Science from these on-demand conference recordings from the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine.

    image

    Overview

    The ASAM Annual Conference is the nation’s premiere event showcasing best practices and the latest science, research, and innovations in addiction medicine. View over 60 high-quality educational sessions on a variety of topics to address your educational needs!

    Learning Objectives

    At the conclusion of this activity, participants should be able to:

    • Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
    • Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
    • Analyze new research and science to develop practical applications for treatment or further research.
    • Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 85 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 85 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 85 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 85 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Who Should Attend

    Healthcare professionals dedicated to increasing access and improving the quality of addiction treatment and care, including:

    • Physicians and Clinicians
    • Researchers and Academics
    • Students and Retirees
    • Counselors and Policymakers
  • Overdose Fatality Reviews: A Data-Driven Collaboration (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about the structure and process of overdose fatality reviews. from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Overdose fatality reviews allow communities to examine and understand the circumstances surrounding fatal drug overdoses. Review teams can uncover the individual and population factors and characteristics of potential overdose victims. Knowing the who, what, when, where, and how of fatal overdoses provides a better sense of the strategies and coordination needed to prevent future overdoses and results in the better allocation of overdose prevention resources and services. This session will provide an overview of overdose fatality review and highlight successes and challenges in the field from local, state and tribal perspectives.  Funding and training and technical assistance opportunities through Bureau of Justice Assistance will be highlighted. There will be a panel of four individuals and the session will include funding and training opportunities from the Bureau of Justice Assistance, an overview of the structure and process of an overdose fatality review, a state level view of the OFR model and features in Wisconsin, and a local level view  in Prince George County Maryland.

    Tara L. Kunkel

    MSW

    Tara Kunkel is presently on detail to the Department of Justice, Bureau of Justice Assistance through an interagency agreement serving as a Senior Drug Policy Advisor.  Ms. Kunkel oversees BJA’s prescription drug monitoring program as well as the Comprehensive Opioid Abuse Program.  Ms. Kunkel graduated from Virginia Commonwealth University with a Masters in Social Work and received her BA in Psychology from the University of Virginia.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Up in Smoke: Igniting Recovery from Tobacco and e-Cigarettes (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 PRA Category 1 Credit(s)™ while learning how to improve nicotine and tobacco research from this conference recording from The ASAM 50th Annual Conference (2019).

    1.5 CME In this conference recording from the 2019 Annual Conference, you will learn that:

    Historically, substance use disorder treatment centers have only offered limited-to-no treatment for tobacco dependence during their programs.  Over the last 30 years, significant gains have been made in behavioral management for tobacco dependence, FDA approval of 7 medications, development of outpatient and inpatient treatment protocols, and the establishment of tobacco-free hospitals and behavioral treatment centers.  In addition, tobacco price elasticity, increased public health knowledge of risks, restrictions in tobacco marketing, and clean, indoor-air laws have resulted in lower tobacco consumption in the general population.  However, these gains have not had enough impact to lower the rates of tobacco-related chronic health diseases in individuals with substance use disorders.  Tobacco use is the number one cause of death for people with alcoholism1 . Furthermore, there are potential threats to the advances already made, including the rapid acceptance of electronic nicotine delivery systems (ENDS) within the last 10 years and the decriminalization and/or legalization of recreational or medical of cannabis use in 30 states over the past two decades. The increasing awareness of tobacco-related, chronic disorders amongst both the public and medical professionals presents an opportune climate for improving the screening and treatment of tobacco dependence in patients receiving treatment for other addictions.  Four potential opportunities include:
     
    1) Dissemination of an increasing number of novel, evidenced-based protocols specifically for individuals with tobacco and co-occurring substance use disorders; 2)  Recognition by medical and behavioral health providers of patient satisfaction and improved outcomes when tobacco is addressed during addiction therapy; 3) Identification, training and collaboration of addiction specialists to advance this concept; and 4)  Awareness of the potential use of ENDS to intentionally deliver other drugs of abuse and need for education of patients and staff about impact of ENDS products on long-term recovery.   This workshop will offer best practices of current evidence-based protocols and provide tools for creating effective treatment options that can be applied in a variety of settings.  The participants will engage in small group, interactive exercises that will develop action plans for addressing tobacco-use disorders within their own treatment settings and on a national level.    Outline: Review important historical milestones in efforts to treat tobacco dependence in addiction settings Discuss potential threats for gains already made in the treatment of tobacco dependence over two decades Discuss potential opportunities and challenges to improve the treatment of tobacco dependence for recovering populations Each participant will be empowered to develop a personalized Strengths, Weakness, Opportunities and Threats (SWOT) analysis of their program during the workshop.

    Learning Objectives:

    Upon completion, participant will be able to:

    Develop 3 novel and effective strategies for improving nicotine and tobacco treatment research, reimbursement, and service delivery.

    Lori D. Karan

    MD, DFASAM, FACP

    Lori Karan, MD, DFASAM, FACP is Professor of Internal Medicine and Preventive Medicine and Director of the Addiction Medicine Fellowship at the Loma Linda University Medical School.   She works in the Substance Treatment and Recovery (STAR) program of the Loma Linda VA Healthcare System (LLVAHCS). During her internal medicine training, Dr. Karan repeatedly treated patients for the consequences of tobacco use.  She recognized that nicotine and tobacco use were often ignored during the treatment of other substance use disorders and that tobacco was the number one cause of death in recovering persons. 

    Dr. Karan guest-edited a seminal issue of the Journal of Substance Abuse Treatment entitled “Towards a Broader View of Recovery.”  These experiences set the foundation for Dr. Karan’s longstanding interest in in the similarities and differences between nicotine and other addictive drugs. Dr. Karan advocated for tobacco control, including befriending the Phillip Morris whistleblower scientists and putting forth stockholder’s proposals during  annual meetings of Phillip Morris, and RJ Reynolds. She received a NIDA Scientist Development Award where she researched the discriminative stimulus effects and neuroendocrine basis for the subjective effect of nicotine.

     Dr. Karan and John Rosecrans PhD co-chaired nine annual ASAM Nicotine Research Round tables and from this excitement originated the Society for Research on Nicotine and Tobacco. More recently Dr. Karan and Dr. Susan Blank authored the Nicotine and Tobacco chapter of the ASAM Criteria where they advocated for increased intensity of treatment for persons who had severe nicotine/tobacco use disorders, medical, and/or psychiatric co-morbidity. Dr. Karan was recruited to LLVAHCS by Dr. Linda Ferry, originator of Zyban.  Dr. Ferry and Dr. Karan continue to develop effective treatments for nicotine and tobacco use, especially in patients who have other substance use disorders. 1 Hurt RD et al.  “Mortality following inpatient addictions treatment.” JAMA 1996 Apr 10; 275(14):1097-1103.

    Laura Martin

    MD, FASAM

    Laura F. Martin, M.D. is an Associate Professor of Psychiatry at the University of Colorado School of Medicine.  She is a board certified psychiatrist and addiction medicine specialist.  She has been recognized as a member of the American College of Psychiatrists, a Fellow of the American Society of Addiction Medicine, and a Distinguished Fellow of the American Psychiatric Association.   Her professional roles include serving as the Medical Director of the Center for Dependence, Addiction and Rehabilitation (CeDAR), Program Director of the Addiction Medicine Fellowship at the University of Colorado School of Medicine, and as President of the Colorado Society of Addiction Medicine.  She regularly works with individuals with both substance use disorders and other behavioral health disorders to improve their physical and mental health and has published peer reviewed research and clinical reviews regarding this work. 

    Linda Hyder Ferry

    MD, MPH

    Chad D. Morris

    PhD

    Chad Morris, Ph.D. is a Professor of Psychiatry at the University of Colorado- School of Medicine, and Director of the Behavioral Health & Wellness Program. He is the principal investigator of many projects and studies exploring the effectiveness of organizational, psychosocial, and pharmacologic wellness and tobacco cessation strategies. As the Vice President of Spark Inspiration, Dr. Morris also offers corporate wellness solutions. He has worked with over 40 states to foster sustainable whole health and tobacco control initiatives for priority populations including persons with mental illnesses, addictions, and justice involved individuals. 

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Expanding Access to Buprenorphine for Justice-Involved Individuals via Mobile Treatment (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to expand access to MAT for justice-involved individuals from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:

    Opioid use disorder (OUD) is highly prevalent among justice-involved individuals.  Despite evidence that increasing access to medications for addiction treatment (MAT) decreases fatal overdoses after release from prison and jail, many barriers to expanding treatment for this population remain.  Most interventions to date have focused on expanding access to MAT inside the criminal justice system, which can work well for those serving longer sentences in prisons, but the high turnover in jails and pre-trial detention centers is not always amenable to starting MAT inside jail. 
     
    In this interactive panel discussion, we will describe the development of Project Connections to Re-Entry (PCARE), a novel treatment model to expand access to buprenorphine for justice-involved individuals.  Started in November 2017, PCARE is part of a network of low-threshold buprenorphine treatment site run by Behavioral Health Leadership Institute (BHLI).  PCARE provides access to low threshold MAT through a mobile van parked directly outside the Baltimore City Jail in partnership with Maryland Department of Public Safety and Correctional Services. Patients are referred by jail staff or can walk in from the street. The clinical team includes an experienced primary care physician who prescribes buprenorphine, a nurse, and a peer recovery coach. Once stabilized, patients are transitioned to longer-term treatment programs or primary care for buprenorphine maintenance.

    Between November 2017 and July 2018, 249 people approached the van, 127 of whom began treatment with buprenorphine-naloxone.  The majority of patients (94.4%) had previous criminal justice involvement, were unemployed (72.4%) and were living with family or friends (41.7%). Of those who began treatment, 67.7% returned for a second visit or more, and 29% percent were still involved in treatment after 30 days. This focus session will begin with brief overview of current literature regarding access to MAT in criminal justice settings.  The interdisciplinary panel, composed of the program director (a lawyer) and physicians, will then describe the process of developing this program, client characteristics and initial outcomes, and implications for expansion to other treatment settings.

    The panel will discuss successes and challenges in partnering with detention center staff and engaging vulnerable populations in care.  After the panel discussion, the group will break into small groups to discuss ways of expanding access to buprenorphine in their own settings.  There will be time at end for Q+A.   Proposed Timeline (in minutes): 0:00 �" 0:10 Brief review of literature related to MAT in criminal justice setting and mobile      treatment models 0:10 �" 0:55 Panel discussion of PCARE low-threshold buprenorphine model 0:55 �" 1:10 Breakout into small groups to discuss expanding treatment in their own settings 1:10 �" 1:30 Questions and Answers/Session Evaluation

    Learning Objectives:

    1.)  Describe current literature on MAT for justice-involved populations.

    2.)  Describe a model of low threshold buprenorphine treatment for justice-involved individuals

    3.)  Identify ways to partner with criminal-justice settings and expand access to MAT for justice-involved individuals in their own geographic area


    Megan Buresh

    MD

    Dr. Megan Buresh is an Assistant Professor of Medicine and Epidemiology at the Johns Hopkins University School of Medicine.  She is board certified in internal medicine and addiction medicine and certified as AAHIVM HIV Specialist.  She received a Bachelor of Arts in Biochemical Sciences from Harvard University (magna cum laude with highest honors in field), completed medical school at Johns Hopkins University School of Medicine and residency at Brigham and Women’s Hospital.  She is the Secretary of the Maryland-DC ASAM Chapter. She is medical director of the Johns Hopkins Bayview Inpatient Addiction Consult Service.  She also provides integrated buprenorphine treatment as part of her outpatient primary care practice.  She is lead physician for BHLI PCARE, a mobile buprenorphine clinic for patients being released from Baltimore City Jail.  Her research interests include public health and addiction, developing and evaluating models to expand office-based opioid treatment, and improving linkages between clinical addiction treatment and community organizations.  She is a co-investigator with the ALIVE study at the Johns Hopkins Bloomberg School of Public Health, where she is studying risk factors for opiate overdose and access to naloxone among persons who inject drugs.    

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • The World of Weird Withdrawal (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to recognize the toxic syndromes that result from strategies patients use to self-treat opioid withdrawal. from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:


    With changing patterns of opioid use, a growing number of patients are at risk for experiencing opioid withdrawal. Due to convenient access to “pseudo-medical” information via social media and purchasing options on the Internet, patients may be using a variety of substances to “self-detox” or to mitigate withdrawal symptoms at home, such as kratom, ibogaine, and loperamide, all of which have potentially toxic effects. Treatment and recovery providers need to be knowledgeable of how patients self-treat opioid withdrawal, and to understand and manage the complications that arise from such practices. Additionally, patients may present with precipitated withdrawal from buprenorphine, naltrexone, or well-intended naloxone administration. These periods of intense withdrawal place patients at risk for medical complications and can jeopardize the early stages of recovery. Understanding the risks and optimizing management using opioid and non-opioid strategies can comfort patients and improve treatment engagement. This session is an interactive case-based workshop in which clinicians will discuss strategies to manage patients with atypical or unusually severe presentations related to opioid self-detoxification and precipitated withdrawal. Cases will illustrate the expected and unintended consequences related to the use of loperamide, kratom, and ibogaine as agents of self-detoxification. Attendees will develop approaches to diagnose and manage the complications of these so-called “alternative” detoxification agents, and learn to identify and treat the withdrawal that develops after regular use of kratom. We will also review the pathophysiology of precipitated withdrawal, discuss strategies to prevent this complication, and examine options to manage severe withdrawal. As there is currently no consensus on the best practices for treating atypical or complex opioid withdrawal, this session will offer an in-depth look at the benefits, risks, and knowledge gaps in rapid buprenorphine induction after naloxone- or naltrexone-precipitated withdrawal, and evaluate the use of other evidence-based agents such as opioid agonists, alpha-2 agonists, gabapentin, and atypical antipsychotics for patients with these multifaceted opioid withdrawal syndromes.  


    Learning Objectives:


    1.)  Recognize the toxic syndromes that result from strategies patients use to self-treat opioid withdrawal.

    2.)  Discuss the varied clinical presentation and management of patients with atypical or complex opioid withdrawal. 

    3.)  Identify methods to minimize the risk of and manage precipitated withdrawal from opioid antagonists or partial agonists.



    Aliana R. Steck

    MD

    Dr. Alaina Steck is a graduate of the Keck School of Medicine at the University of Southern California, did her residency training in Emergency Medicine at Boston Medical Center, and completed fellowship at the Emory University / Centers for Disease Control and Prevention Joint Fellowship in Medical Toxicology. She is board-certified in Emergency Medicine, Medical Toxicology, and Addiction Medicine, and practices all three clinical specialties at Grady Memorial Hospital in Atlanta, Georgia. She serves as an assitant medical director at the Georgia Poison Center and the medical director of the Grady Medication-Assisted Opioid Treatment clinic.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Enhancing Motivation, MAT Adherence & Retention with Routine Use of Contingency Management (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to describe the foundation for enhanced treatment outcomes in SUD patients using contingency management from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that Contingency Management (CM) is the best-researched, most effective -- yet least utilized -- treatment innovation in addiction. After a half-century of research, clinicians still have numerous concerns: ethics (is it enabling to pay patients money?), resources (where will the money come from?), testing (frequent and visually witnessed drug testing?) & management (who will do the intricate accounting?). Technology can surmount each of these obstacles, with the added plus of patient engagement & relapse/dropout prediction. Providers will describe technology's potential for enhancing motivation, improving MAT adherence, & extending treatment retention. Data from thousands of patient events with several different technologic tools indicates that these approaches are feasible with many types of: Substance use disorders (from tobacco smoking to opioids) Subpopulations (from pregnant women to criminal justice-involved returning citizens to corporate executives) Providers (from counselors to case managers to recovery coaches), and Settings (from medical centers to recovery homes to national insurance companies). Finally, large data (e.g.,  < 90,000 financial transaction events from 1,400 patients) can generate imminent dropout and relapse indicators with good validity (e.g., 70% positive predictive value) that can be used to issue real-time alerts to providers to intervene -- even prior to a patient's return to drug use, allowing rapid treatment intensification without the need for repeat detoxification to address withdrawal. Impacts range from decreased drinking, to longer treatment retention to meaningful program completion (e.g., improving graduation rates from 67% to 87% within a justice-system involved long-term rehabilitation). Attendees will workshop how to achieve practical implementation within busy, oversubscribed and scarcely-resourced practices and treatment programs in the midst of an epidemic.


    Learning Objectives:

    1.) Explain the obstacles that have prevented wide-spread adoption of contingency management in routine care.

    2.) Describe the research foundation for enhancing treatment outcomes in patients with substance use disorders using contingency management. 

    3.) Analyze the utility of various new technologies that have been proposed and implemented to overcome the obstacles to adoption of contingency management.

    David Gastfriend

    MD, DFASAM

    David R. Gastfriend, MD, served on the faculty of Harvard Medical School for 25 years, most recently as Director of the Addiction Research Program at Massachusetts General Hospital (MGH). His studies of the Patient Placement Criteria published by the American Society of Addiction Medicine (ASAM) have been supported by the NIH's National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the U.S. Centers for Disease Control, U.S. state governments, managed care corporations, including Aetna Behavioral Healthcare, and foreign governments, including Belgium, Finland, Iceland, Israel, Norway, Switzerland, and the World Health Organization. The author of over 125 scientific publications, he has served on the Boards and Editorial Boards of a number of societies and journals, including ASAM and the International Society of Addiction Medicine (ISAM). He is co-editor of the leading book on treatment matching in the field, The ASAM Patient Placement Criteria for Substance-Related Disorders and editor of Addiction Treatment Matching. In addition to his role at RecoverySearch, Dr. Gastfriend is also Vice President for Scientific Communications at Alkermes, Inc. (NASDAQ: ALKS) where he is involved in research, education and scientific publication on extended-release naltrexone (VIVITROL®) and the company's efforts in the field of addiction treatment.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Opening Scientific Plenary & Distinguished Scientist Lecture (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to understand and mitigate risk factors leading up to drug use from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:

    The Special ASAM 50th Annual Conference begins with an energizing Opening Scientific Plenary Session and highlights from the past 50 years. Moderated by ASAM President Kelly J. Clark, MD, MBA, DFAPA, DFASAM, distinguished presenters of the opening session will focus on incredible cutting-edge science in addiction medicine and a new paradigm of hope for prevention and treatment. Nora D. Volkow, MD Science Advances in the Prevention and Treatment of Opioid Addiction The misuse of and addiction to opioids"including prescription pain relievers, heroin, and synthetic opioids such as fentanyl"has resulted in a national crisis that we have not yet been able to revert. This presentation will highlight how NIH researchers are using scientific advances being made to turn the tide in the opioid crisis through the development of: new medications to treat pain; innovative drug abuse prevention strategies that can mitigate an individual’s vulnerability to addiction; and promising strategies that can successfully treat opioid use disorder and prevent and reverse overdose. Bankole Johnson Personalizing the Treatment for Alcohol Use Disorders This presentation will characterize the development of a genetic-based treatment for alcohol use disorders from animals to humans as well as prospects for regulatory approval. What is the genetic loading for alcohol use disorder? What is an inverted U-shaped dose curve? What is the frequency of the target genetic cohort for the treatment of alcohol use disorders? David & Nic Sheff A New Paradigm Facing America's Drug Use and Addiction Crises We're in crisis, but there's hope. The hope is a new paradigm for preventing and treating drug use and addiction in America. For prevention, we focus on drugs, but the key to prevention is a recognition of why people use them--understanding and mitigating risk factors. For treatment: We're at the beginning of a sea change as we reject failed efforts of the past -- ones based on the view that addiction is a choice -- and replace it with one based on the science of addiction medicine. We've a long way to go at a time we're losing more people under 50 from overdose than anything else. But we have a roadmap.
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Designer Drugs Update 2019: Phenibut, Synthetic Opioids, & More (1.5 CME)

    Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to recognize clinical clues to intoxication with emerging designer drugs, and ways to differentiate from other drug use from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that/about:

    Learning Objectives:

    1.) Identify emerging designer drugs, including phenibut, synthetic opioids, and others.

    2.) Recognize clinical clues to intoxication with emerging designer drugs, and ways to differentiate from other drug use.

    3.) Discuss treatment of medical and psychiatric complications resulting from use of designer drugs.

    Patterns of drug abuse are constantly changing. This is particularly the case regarding new psychoactive substances or designer drugs, in which new variants are continually emerging with uptake especially among young adults. New synthetic designer drugs can be challenging to identify and treat effectively, especially serious medical and psychiatric complications. This is important for practitioners, as new designer drugs have resulted in multiple deaths, as well as other significant health consequences to users. This session will educate practitioners about several newer designer drugs regarding use trends along with psychotropic and health effects. Session description: This focus session will inform attendees with a discussion�"including clinical case examples�"that will focus on emerging designer drugs, including phenibut, synthetic opioids, and others. Use of these drugs has caused significant medical and psychiatric consequences, including multiple deaths, which has received recent media attention.  The presentation will be evidence-based and draw from existing medical literature, and will also include the panelists’ clinical experience with patients experiencing designer drug use and complications. The emphasis will be on clinical issues, especially recognition of intoxication, problems related to detection with urine drug testing, and treatment of medical and psychiatric complications. Attention will be given to specific populations that have been shown to be using these designer drugs. The presenters are experienced clinicians who have been involved in evaluation of patients using designer drugs. The presenters have also published about designer drugs in peer-reviewed journals. Attendees will be able to share their own experiences with patient use of designer drugs to enrich the discussion. Time will be allowed for questions to the panelists so that there will be significant interaction during this focus session. Conclusions: This focus session will provide attendees with evidence-based clinical knowledge to help identify and treat complications from newer designer drug use, especially those with life-threatening complications.  

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Big Ideas Plenary (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning what ideas are shaping the future of addiction medicine from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    What big ideas are shaping the future of addiction medicine? Draw inspiration from ASAM award recipients and insight from national innovators during the Big Ideas Plenary Session. ASAM President Kelly J. Clark, MD, MBA, DFAPA, DFASAM, will recognize award recipients on-stage and with personalized video clips of individuals making major contributions to the field. She will also moderate an informal fireside chat with representatives from the National Institute of Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the Office of the Surgeon General. Agency leaders will each give a five-minute presentation on one innovative big idea from their respective institutions. The session will conclude with stimulating questions and lively conversation.

    Nora Volkow, MD

    Director, National Institute on Drug Abuse, National Institutes of Health

    Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. Her work has been instrumental in demonstrating that drug addiction is a disease of the human brain. She pioneered the use of brain imaging to investigate the toxic effects and addictive properties of abusable drugs and has also made important contributions to the neurobiology of obesity, ADHD, and aging.

    Dr. Volkow was born in Mexico, earned her medical degree from the National University of Mexico, and carried out her psychiatric residency at New York University. Prior to her tenure at NIDA she held leadership positions at the Department of Energy's Brookhaven National Laboratory including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. She was also a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)-Stony Brook.

    Dr. Volkow has published more than 600 scientific articles and edited three books on neuroimaging for mental and addictive disorders. Among her many awards have been selection for membership in the Institute of Medicine, and the International Prize from the French Institute of Health and Medical Research. She was also named one of Time Magazine's “Top 100 People Who Shape our World", included as “One of the 20 People to Watch" by Newsweek magazine, and named “Innovator of the year" by U.S. News & World Report in 2000.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Harm Reduction in the Addiction Continuum: Not as Radical As One Thinks (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how harm reduction can be used in clinical practice from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:

    Learning Objectives:


    1.) Review the definition and background of harm reduction and demonstrate that it is congruent with the management of patients with other chronic relapsing illnesses.

    2.) Describe case examples of patients who benefit from low threshold or harm reduction care to keep them engaged, and to lower the risks associated with ongoing substance use.

    3.) Identify opportunities for integrating harm reduction into your own practice.

    The hallmark of addiction is loss of control and ongoing compulsive substance use despite negative consequences and is underscored by significant difficulty in executive functioning and organization.  As such, especially early on in care or at a time of relapse, highly structured treatment modalities and scheduling are unrealistic for many at best, and potentially lethal for others at worst.   If late or missed appointments result in longer waits or missed opportunities for care, or substance use results in discharge from care or referral to a higher level of care when the patient is either not able or ready to make such a change, the result can be no level of care. Despite prescription drug monitoring programs, misuse deterrent opioid formulations, expanded education efforts for safe pain prescribing and SUD screening and management, increased buprenorphine trainings and expanded waivers, the substance use disorder treatment gap remains and the opioid overdose epidemic continues to soar.  The landscape of the opioid epidemic has changed even more dramatically with fentanyl and carfentanyl, requiring more readily available care and flexible care models to help keep people engaged in care, while we work with them through the natural history of substance use disorder.  By partnering with patients in this manner, we help keep them alive, lower their risk of ongoing serious health complications or overdose, and increase their chances of continuing to engage in meaningful treatment; we collaborate with them in the practice of harm reduction. The session organizers will review harm reduction as patient centered care congruent with the practice of all medical specialties.    They will describe specific case examples of how harm reduction can be used in clinical practice, review flexible care models to engage patients with ambivalence or other competing life priorities, and explore ways to gain buy-in from colleagues in order to shift culture and increase comfort in providing harm reduction care within their continuum. The second half of the session will be spent in small groups where participants will review potential barriers to incorporating harm reduction into practice and explore how they would envision operationalizing and providing such care within their current practice.  

    Laura G. Kehoe

    MD, MPH, FASAM

    Dr. Kehoe is an Assistant Physician at Massachusetts General Hospital and an Assistant Professor of Medicine at Harvard Medical School and is board certified in both Internal Medicine and Addiction Medicine.  She attended Tufts University School of Medicine and Boston University School of Public Health and completed her residency in Internal Medicine at Massachusetts General Hospital.   At Massachusetts General Hospital, she is the Medical Director of the Substance Use Disorder Bridge Clinic, an immediate access, urgent care addiction program.   She is actively involved in medical student and resident education as an attending physician on the inpatient Addiction Consult Team (ACT), and she is the co-chair of the hospital-wide Substance Use Disorder Education Committee, where she works with other team members to expand evidence-based treatment of patients with addiction. 

    Outside of MGH, she was the Medical Director of Baycove Treatment Center for Opiate Addictions Methadone Maintenance program and she treats patients as part of a multidisciplinary addiction team at the supportive housing and outpatient non-profit, Right Turn.   Lastly, Dr. Kehoe is a founding member of W.A.T.E.R.town (Watertown Access to Treatment Education and Recovery), a community coalition working to expand prevention, intervention and treatment for people with substance use disorder in Watertown, MA.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Pharmacotherapy Studies to Prevent Opioid Relapse Following Jail Release: Lessons Learned (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about opioid addiction problems in jail from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:


    Opioid use disorder (OUD) in US jail populations is a major public health concern. Individuals with OUD who do not receive treatment during incarceration have high rates of relapse and are exposed to increased risk of overdose death upon release. Despite the proven effectiveness of methadone and extended release naltrexone treatment for OUD, these medications are rarely initiated prior to release from jail. The National Institute on Drug Abuse funded a cooperative study consisting of three randomized clinical trials to examine the effectiveness of pharmacotherapy initiated prior to release from jails in Albuquerque, NM, Baltimore, MD, and New York, NY. These studies randomly assigned opioid-addicted adults in jail to begin: methadone treatment with or without patient navigation, or an enhanced treatment as usual condition (in Baltimore, N=225); to extended release naltrexone with and without patient navigation, or enhanced treatment as usual (in Albuquerque, N=150); and, to extended release naltrexone or enhanced treatment as usual (in New York, N=255). This series of presentations will outline the scope of the opioid addiction problem in jails, the rationale and use of these medications in jails, challenges in implementing these approaches in jail and post-release, and medical and psychiatric co-morbidities in this patient population.  Main results to date will be presented, including: patient willingness to be treated, rates of study treatment retention after release, and community drug treatment outcomes. Audience discussion surrounding opioid treatment in criminal justice settings will be encouraged.

    Learning Objectives:


    1.) Participants will be able to list three challenges to implementing pharmacotherapy for opioid addiction in jails.
    2.) participants will be able to describe the benefits of providing methadone and extended release naltrexone prior to release from jail.
    3.) participants will be able to describe the role of patient navigation in linking patients to opioid addiction treatment across the jail to community treatment chasm.


    Robert P. Schwartz

    MD

    Dr. Schwartz is a psychiatrist and Medical Director of the Friends Research Institute. He is Co-Principal Investigator of the Mid-Atlantic Node of the National Institute on Drug Abuse (NIDA) Clinical Trials Network. He has studied pharmacotherapy for Opioid Use Disorder in the community and in jail and prison through numerous NIDA grant award and has over 150 scientific publications. Dr Schwartz is Associate Professor of Psychiatry and is the recipient of the Dole-Nyswander Award from the American Association for the Treatment of Opioid Dependence.

    Joshua D. Lee

    MD, MSc, FASAM

    Joshua D. Lee MD, MSc is an Associate Professor in the Departments of Population Health and Medicine at the NYU School of Medicine. He is board-certified in Internal Medicine and Addiction Medicine and is a physician at Bellevue Hospital Center, NYU Langone Medical Center, and in the NYC jails. He directs the NYU ABAM Fellowship in Addiction Medicine. His research focuses on novel and medication treatments for addiction among criminal justice and primary care populations.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • Opioid Misuse, Overdose, and Suicide: Correlates and Intervention Strategies (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about opioid use and chronic pain as risk factors for suicide and/or overdose risk from this conference recording from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:


    According to 2016 NSDUH, 2 million adults (aged 18 or older) met criteria for an opioid use disorder (OUD) and 42,000 of overdose deaths are attributable to opioids. In the same year, an estimated 1.3 million adults attempted suicide. It is estimated that over 11million US adults experience daily pain. Various studies have concluded that depression and pain frequently co-occur and increase the risk for suicidal behaviors/suicide or overdose. However, the intersection among these conditions is often complex and contributions not well established. Furthermore, in the context of chronic pain or OUD, determining the cause of death as either a drug overdose or suicide is a challenge due to the entwined nature of these conditions. However, the evidence base to inform clinicians in the selection and sequencing of effective treatment strategies is limited. In this symposium, we propose to characterize these populations and disentangle some of these complex associations among chronic pain, opioid misuse/OUD, and risk for suicide and overdose.  The talks will highlight the correlates and risks in patients exposed to prescription opioids as well as those who have OUD. Content also includes some suggestions for methods to identify key risk, and provide a review of the evidence for prevention interventions to reduce suicide, factors in these populations. The final speaker will review the literature on effective treatments for OUD and Depression and discuss its potential for lowering OD/suicide risks.   
    1.) Recognize the prevalence and correlates of opioid use and chronic pain as risk factors for suicide and/or overdose risk
    2.) Identify ways to identify these risk factors and become familiar with prevention interventions to reduce the risk for suicide
    3.) Review the existing literature on combining or integrating depression and OUD treatments with the aim of lowering risk for overdose or suicide.




    Geetha Subramaniam

    MD., DFAPA, DFAACAP

    Dr. Subramaniam is the Deputy Director of the Center for Clinical Trials Network, at NIDA. In this role, she has been instrumental in developing research projects in a variety of topic areas, including addressing the prevention of substance abuse in adolescents, prevention and intervention of prescription stimulant misuse in youth. Previously, she was a full-time faculty member in the Division of Child Psychiatry at Johns Hopkins School of Medicine and the Associate Medical Director of Mountain Manor Treatment Center, Baltimore, MD, where she led clinical trials with adolescents with SUD and served as a preceptor to residents and fellows. She distinguished herself as a clinical and research expert in the assessment and treatment of adolescents and young adults with opioid use disorders. She is ABPN certified in General, Child, and Adolescent, and Addiction Psychiatry and a Distinguished Fellow of both the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry.

    Martin D. Cheatle

    PhD

    Dr. Martin Cheatle, Clinical Psychologist, Director, Behavioral Medicine at Penn Pain Medicine Center earned his PhD in psychology at Princeton University. He completed his clinical internship at the University of Pennsylvania, School of Medicine and founded the Orthopaedic Pain Center at PENN. Currently he is Director of Behavioral Medicine at the PENN Pain Medicine Center and Director, Pain and Chemical Dependency Research at the Center for Studies of Addiction, University of Pennsylvania. He is an Associate Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania.  Dr. Cheatle specializes in the evaluation and treatment of chronic pain disorders from a biopsychosocial perspective and has been involved in extensive research including a NIH funded 5-year longitudinal study of the development of addiction in patients initiating prescription opioid therapy for chronic pain and as PI of a currently funded NIH/NIDA grant assessing phenotypic and genotypic markers of prescription opioid abuse.  His main focus of research is pain management and addiction in vulnerable populations (HIV/AIDS, psychiatric patients) and pain and suicidal ideation and behavior. 

    Mark Ilgen

    PhD

    Mark A. Ilgen, Ph.D. is a clinical psychologist, a professor of psychiatry, and an investigator with the VA Center for Clinical Management Research (CCMR) at the VA Ann Arbor Healthcare System. Much of his current work focuses on improving treatment outcomes for patients struggling with substance use disorders and complicated co-occurring problems, particularly chronic pain, other psychiatric disorders, and suicide risk. In working with adults who have drug and alcohol problems, his goal is to help them reverse the course of addiction as quickly as possible to minimize the damaging effects on other areas of their lives. For individuals grappling with both addiction and chronic pain, Dr. Ilgen has developed an intervention that can help address both problems and also minimize the treatment challenges that opioids, cannabis and alcohol often present for this population. He is in the process of conducting research to determine the potential effectiveness of this intervention. Dr. Ilgen is also keenly interested in evaluating addiction treatment approaches to identify the factors most important to patient motivation, quality of life during treatment, and outcomes. He is also the principal investigator of a study to better understand marijuana use for pain management and the potential implications for patient outcomes as well as health policy.

    Richard Ries

    MD, F.A.P.A., F.A.S.M

    RICHARD K. RIES, MD Professor, Director, Addictions Division Department of Psychiatry and Behavioral Sciences University of Washington School of Medicine Seattle, Washington Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington, and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident. Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and has been involved with numerous research grants from the National Institute of Health. In addition he has been active in both studying and treating persons with opioid use disorders, with involvement in SAMHSA grants and the Harborview Addictions program opioid treatment tracks. He has been senior editor of the key reference text: Principles of Addiction Medicine (editions IV and V, published by the American Society of Addiction Medicine, and a noted expert in the field of Addictions, Suicide and other Co-occurring Disorders.

    Edward Nunes

    MD

    Dr. Nunes is a Professor of Psychiatry, and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) clinical Trials Network as well as other NIDA funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing studies include treatments for cocaine dependence in general, heroin and other opioid dependence, for nicotine dependence in general, and for addicted patients with co-occurring psychiatric disorders including depression, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone, buprenorphine, mirtazapine) as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Dr. Nunes also studies the challenges involved in implementing evidence-based treatments for substance use disorders in real-world community-based treatments settings. Dr. Nunes also serves on the American Board of Addiction Medicine, Co-Chair of the Columbia/ New York State Psychiatric Institute's Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

  • An Assertive Approach for Youth OUD: Family Engagement and Medication Home Delivery (1.5 CME)

    Product not yet rated Contains 4 Component(s), Includes Credits

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about clinical models for the treatment of youth with opioid use disorders from The ASAM 50th Annual Conference (2019).

    (1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:


    Young people are disproportionately affected by the current opioid epidemic, with catastrophic consequences for youth and their families. But adolescents and young adults with OUD generally have poor engagement in care, and worse treatment outcomes than older adults. Fewer than 25% of adolescents with OUD receive any relapse prevention medication.  Despite the clear and urgent need, there is still a lack of research and clinical consensus on youth-specific treatment models. In particular, while we have evidence for effectiveness of medications, we have little evidence for the most effective delivery models for these medications. We have a long way to go in optimizing engagement and retention. Assertive interventions, including home delivery of medication,s have had a role in overcoming barriers to retention and adherence in numerous chronic relapsing-remitting illnesses, including Assertive Community Treatment (ACT) for severe and persistent mental illness.  This session will feature an innovative approach to treatment for high-severity OUD in youth, including assertive outreach, family engagement and home delivery of relapse prevention medications. The session will begin with a description of the intervention. Family engagement empowers families, providing guidance for monitoring and improving adherence for youth in treatment. Confidentiality is sometimes seen as a barrier, and young adults may have developmentally normative resistance to involving their families. But respecting the emerging autonomy of youth and including families are not incompatible with one another. In fact, treatment of youth proceeds best as a collaboration among youth, parents and the treatment team. Additionally, clinic-based treatment can present barriers to treatment access. Home-based services, including monthly administration of extended release naltrexone or extended release buprenorphine, have the potential to overcome many of these barriers. By literally meeting youth and families where they are, in their homes, we may be able to engage and retain youth that are not be likely to succeed in clinic-based settings. The workshop will continue with an interactive discussion of cases vignettes that illustrate the non-linear clinical courses characteristic of this patient population, the decision points in clinical trajectories, and the conundrums in management. There will be a particular focus on practical clinical strategies in leveraging family involvement. Finally, the session will summarize results to date in evaluating the model. Our small published case series (Vo et al , 2017) showed promising results with an increase in retention and number of doses received, compared to a historical comparison group of clinic-based treatment as usual. In an interim analysis of the first 25 subjects in a randomized trial currently underway, preliminary results show that the intervention group had a significantly greater mean number of doses over the first 3 months (2.5 doses) compared to the usual care control (0.3 doses). The intervention group also had a lower rate of OUD relapse (27%) than the control group (91%). There will also be ample opportunity throughout for Q&A and discussion.  



    Learning Objectives:


    1.) Describe limitations to clinic based clinical models for the treatment of youth with opioid use disorders 
    2.) Describe developmental vulnerabilities of youth that act as barriers to access, engagement and retention
    3.) Describe approaches to overcoming barriers to care for youth with OUDs 


    Marc J. Fishman

    MD, DFASAM

    Marc Fishman MD is board certified in addiction psychiatry and addiction medicine. A faculty member of the Johns Hopkins University School of Medicine, he is Medical Director and CEO of Maryland Treatment Centers, a regional behavioral health care provider, with inpatient and outpatient facilities for adolescents and adults. His clinical specialties include treatment of drug-involved and dual-diagnosis adolescents, opioid dependence in adolescents and adults, and co-occurring disorders. He has been principal investigator or collaborator for several NIDA- and CSAT-funded projects to improve and evaluate adolescent treatment, as well as pharmacotherapy trials in adults. He is the author of numerous articles and book chapters on addiction treatment, and lectures widely on a variety of topics including adolescent treatment, youth opioid treatment, placement and treatment matching strategies. Dr. Fishman served as a co-editor for the most recent editions of ASAMs Patient Placement Criteria, leading the adolescent section, and served as the chief editor for the ASAM PPC Supplement on Pharmacotherapies for Alcohol Use Disorders. He is the chair of the Adolescent Committee for ASAM. He is a Past President of the Maryland Society of Addiction Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    ABIM Maintenance of Certification (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.